Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 7/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520375 | 0.89 | LPL (0.44) | LNPEPNAMPTGPR119SRD5A1LMNA | |
| SCHEMBL6525322 | 0.88 | P2RX3 (0.39) | LNPEPNAMPTHRH3LIPE | |
| SCHEMBL6522916 | 0.86 | LNPEP (0.37) | LNPEPNAMPTGPR119 | |
| SCHEMBL6522082 | 0.86 | SRD5A1 (0.41) | LNPEPNAMPTGPR119SRD5A1LMNA | |
| SCHEMBL6518444 | 0.86 | CYP11B2 (0.40) | LNPEPNAMPTGPR119SRD5A1ALDH1A1 | |
| SCHEMBL6522441 | 0.86 | GPR119 (0.41) | LNPEPNAMPTGPR119SRD5A1LMNA | |
| SCHEMBL6523540 | 0.86 | HMOX1 (0.39) | LNPEPNAMPTGPR119HRH3LIPE | |
| SCHEMBL6520372 | 0.85 | EPHX2 (0.44) | NAMPTSRD5A1LMNAMAPTKMT2A | |
| SCHEMBL6524637 | 0.84 | ACACB (0.39) | LNPEPNAMPTGPR119HRH3 | |
| SCHEMBL6525436 | 0.84 | CHRM4 (0.41) | NAMPTGPR119CYP4F2CYP4A11LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | LNPEP 4680/4885NAMPT 1696/4885GPR119 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.